James Suen
Concepts (310)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arteriovenous Malformations | 9 | 2018 | 66 | 1.700 |
Why?
| Head and Neck Neoplasms | 14 | 2012 | 335 | 1.360 |
Why?
| Carcinoma, Squamous Cell | 12 | 2011 | 384 | 0.920 |
Why?
| Neck | 7 | 2018 | 116 | 0.760 |
Why?
| Vascular Malformations | 3 | 2010 | 101 | 0.710 |
Why?
| Head | 5 | 2018 | 77 | 0.680 |
Why?
| Patients | 1 | 2018 | 53 | 0.630 |
Why?
| Terminal Care | 1 | 2018 | 56 | 0.620 |
Why?
| Hemangioma | 3 | 2018 | 83 | 0.600 |
Why?
| Laryngectomy | 3 | 2013 | 28 | 0.590 |
Why?
| Attitude to Health | 1 | 2018 | 226 | 0.570 |
Why?
| Laryngeal Neoplasms | 2 | 2007 | 55 | 0.550 |
Why?
| Carcinoma, Merkel Cell | 4 | 2016 | 47 | 0.500 |
Why?
| Laser Therapy | 3 | 2011 | 91 | 0.490 |
Why?
| Quality of Life | 3 | 2012 | 922 | 0.490 |
Why?
| Laryngeal Diseases | 1 | 2013 | 14 | 0.450 |
Why?
| Herpes Simplex | 1 | 2013 | 24 | 0.450 |
Why?
| Parotid Diseases | 1 | 2012 | 4 | 0.450 |
Why?
| Neuromuscular Agents | 1 | 2012 | 7 | 0.450 |
Why?
| Nuclear Proteins | 6 | 2015 | 252 | 0.440 |
Why?
| Botulinum Toxins, Type A | 1 | 2012 | 14 | 0.440 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 8 | 0.420 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 10 | 0.420 |
Why?
| Lasers, Dye | 1 | 2011 | 10 | 0.420 |
Why?
| Eating | 1 | 2012 | 155 | 0.410 |
Why?
| Photosensitizing Agents | 1 | 2011 | 24 | 0.410 |
Why?
| Photochemotherapy | 1 | 2011 | 37 | 0.400 |
Why?
| Survivors | 1 | 2012 | 137 | 0.400 |
Why?
| Cheek | 1 | 2010 | 9 | 0.370 |
Why?
| Lip | 1 | 2010 | 11 | 0.370 |
Why?
| Flow Cytometry | 6 | 2019 | 546 | 0.360 |
Why?
| Female | 29 | 2018 | 28441 | 0.360 |
Why?
| Facial Neoplasms | 1 | 2010 | 23 | 0.360 |
Why?
| Neoplastic Cells, Circulating | 4 | 2019 | 93 | 0.360 |
Why?
| Humans | 48 | 2019 | 54284 | 0.360 |
Why?
| Receptors, Progesterone | 1 | 2009 | 57 | 0.350 |
Why?
| Middle Aged | 20 | 2018 | 13088 | 0.350 |
Why?
| Pain | 1 | 2012 | 405 | 0.350 |
Why?
| Male | 29 | 2018 | 27334 | 0.350 |
Why?
| Lymphatic Vessels | 1 | 2009 | 47 | 0.340 |
Why?
| Aged | 16 | 2018 | 10054 | 0.340 |
Why?
| Postoperative Complications | 3 | 2012 | 1033 | 0.340 |
Why?
| Adult | 20 | 2017 | 14207 | 0.320 |
Why?
| Skin Neoplasms | 4 | 2016 | 532 | 0.320 |
Why?
| Recurrent Laryngeal Nerve | 1 | 2007 | 20 | 0.320 |
Why?
| Laryngeal Nerves | 1 | 2007 | 19 | 0.320 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 1056 | 0.320 |
Why?
| Surgical Flaps | 1 | 2009 | 135 | 0.310 |
Why?
| Neoplasms | 1 | 2018 | 1316 | 0.310 |
Why?
| Factor VII | 1 | 2007 | 3 | 0.310 |
Why?
| Melanoma | 2 | 2022 | 313 | 0.300 |
Why?
| Intracranial Arteriovenous Malformations | 1 | 2007 | 28 | 0.300 |
Why?
| Dilatation | 2 | 2017 | 27 | 0.290 |
Why?
| Gene Silencing | 4 | 2009 | 129 | 0.250 |
Why?
| Disease Models, Animal | 3 | 2016 | 1639 | 0.240 |
Why?
| Adolescent | 10 | 2012 | 6897 | 0.230 |
Why?
| Cell Proliferation | 4 | 2016 | 1096 | 0.220 |
Why?
| Melanoma, Experimental | 2 | 2016 | 49 | 0.220 |
Why?
| Retrospective Studies | 10 | 2015 | 6432 | 0.220 |
Why?
| Muscarinic Agonists | 1 | 2002 | 12 | 0.220 |
Why?
| Xerostomia | 1 | 2002 | 3 | 0.220 |
Why?
| Immunohistochemistry | 8 | 2014 | 1089 | 0.220 |
Why?
| Sjogren's Syndrome | 1 | 2002 | 14 | 0.220 |
Why?
| Endoscopy | 2 | 2015 | 131 | 0.210 |
Why?
| Thiophenes | 1 | 2002 | 37 | 0.210 |
Why?
| Plasmodium yoelii | 1 | 2022 | 17 | 0.210 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2013 | 84 | 0.210 |
Why?
| Quinuclidines | 1 | 2002 | 42 | 0.210 |
Why?
| Promoter Regions, Genetic | 7 | 2015 | 520 | 0.210 |
Why?
| Treatment Outcome | 7 | 2018 | 5604 | 0.210 |
Why?
| Malaria | 1 | 2022 | 37 | 0.210 |
Why?
| Veins | 3 | 2010 | 74 | 0.200 |
Why?
| Azepines | 3 | 2016 | 22 | 0.200 |
Why?
| Embolization, Therapeutic | 3 | 2011 | 98 | 0.190 |
Why?
| Transcription Factors | 2 | 2015 | 622 | 0.190 |
Why?
| Triazoles | 3 | 2016 | 120 | 0.180 |
Why?
| Child | 10 | 2012 | 7341 | 0.170 |
Why?
| Neoplasm Invasiveness | 3 | 2010 | 295 | 0.170 |
Why?
| Child, Preschool | 8 | 2012 | 4147 | 0.170 |
Why?
| Mast Cells | 1 | 2018 | 64 | 0.160 |
Why?
| Ki-67 Antigen | 3 | 2013 | 63 | 0.160 |
Why?
| Cricoid Cartilage | 1 | 2017 | 9 | 0.160 |
Why?
| Combined Modality Therapy | 4 | 2018 | 692 | 0.150 |
Why?
| Mice | 10 | 2022 | 6413 | 0.150 |
Why?
| Estradiol | 1 | 2018 | 219 | 0.150 |
Why?
| Trachea | 1 | 2017 | 51 | 0.150 |
Why?
| Mice, Nude | 5 | 2016 | 283 | 0.150 |
Why?
| Lasers, Semiconductor | 2 | 2022 | 10 | 0.140 |
Why?
| Qualitative Research | 1 | 2018 | 331 | 0.140 |
Why?
| Embolism | 1 | 2016 | 27 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2011 | 2387 | 0.140 |
Why?
| Infant | 7 | 2018 | 3817 | 0.140 |
Why?
| Benzoxazoles | 1 | 2016 | 12 | 0.140 |
Why?
| Biopsy | 3 | 2015 | 692 | 0.140 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2016 | 64 | 0.140 |
Why?
| Neoplasm Staging | 2 | 2010 | 806 | 0.140 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2016 | 93 | 0.140 |
Why?
| Tracheotomy | 1 | 2015 | 14 | 0.140 |
Why?
| Tracheal Stenosis | 1 | 2015 | 10 | 0.140 |
Why?
| Laryngostenosis | 1 | 2015 | 10 | 0.130 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2016 | 85 | 0.130 |
Why?
| Proto-Oncogene Proteins c-myb | 1 | 2015 | 9 | 0.130 |
Why?
| Photoacoustic Techniques | 1 | 2016 | 86 | 0.130 |
Why?
| Larynx | 2 | 2017 | 39 | 0.130 |
Why?
| Aged, 80 and over | 6 | 2015 | 3431 | 0.130 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 55 | 0.120 |
Why?
| Pyrimidines | 1 | 2016 | 196 | 0.120 |
Why?
| Fluorouracil | 2 | 2004 | 61 | 0.120 |
Why?
| Disease Progression | 3 | 2014 | 913 | 0.120 |
Why?
| DNA Methylation | 5 | 2009 | 574 | 0.120 |
Why?
| Carcinoma | 2 | 2012 | 153 | 0.120 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 866 | 0.120 |
Why?
| Breast Neoplasms | 2 | 2015 | 1248 | 0.110 |
Why?
| Mastication | 1 | 2012 | 7 | 0.110 |
Why?
| Trismus | 1 | 2012 | 4 | 0.110 |
Why?
| Apoptosis | 2 | 2016 | 1300 | 0.110 |
Why?
| Adaptor Proteins, Signal Transducing | 3 | 2009 | 208 | 0.110 |
Why?
| Radiotherapy, Adjuvant | 1 | 2012 | 66 | 0.110 |
Why?
| Animals | 10 | 2022 | 14385 | 0.110 |
Why?
| DNA, Neoplasm | 2 | 2011 | 171 | 0.110 |
Why?
| Receptors, Cell Surface | 1 | 2013 | 130 | 0.110 |
Why?
| Recurrence | 2 | 2011 | 690 | 0.110 |
Why?
| Lymphangioma, Cystic | 1 | 2011 | 8 | 0.110 |
Why?
| Chemoradiotherapy | 1 | 2012 | 42 | 0.100 |
Why?
| Endothelium, Lymphatic | 1 | 2011 | 13 | 0.100 |
Why?
| Cisplatin | 2 | 2004 | 352 | 0.100 |
Why?
| Syndrome | 1 | 2012 | 252 | 0.100 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.100 |
Why?
| Enteral Nutrition | 1 | 2012 | 136 | 0.100 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 399 | 0.100 |
Why?
| Antigens, CD | 1 | 2013 | 242 | 0.100 |
Why?
| Lymphatic Abnormalities | 1 | 2011 | 22 | 0.100 |
Why?
| Deglutition Disorders | 1 | 2012 | 71 | 0.100 |
Why?
| Propranolol | 1 | 2012 | 78 | 0.100 |
Why?
| Immunoenzyme Techniques | 4 | 2016 | 165 | 0.100 |
Why?
| Microtubule-Associated Proteins | 1 | 2011 | 78 | 0.100 |
Why?
| Homeodomain Proteins | 1 | 2011 | 82 | 0.100 |
Why?
| Brain Neoplasms | 1 | 2014 | 284 | 0.100 |
Why?
| Tumor Suppressor Proteins | 1 | 2011 | 141 | 0.100 |
Why?
| Weight Gain | 1 | 2012 | 243 | 0.100 |
Why?
| Epigenomics | 1 | 2011 | 67 | 0.100 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1136 | 0.090 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2016 | 219 | 0.090 |
Why?
| Risk Assessment | 1 | 2015 | 1361 | 0.090 |
Why?
| Lip Neoplasms | 1 | 2010 | 4 | 0.090 |
Why?
| Diagnostic Imaging | 1 | 2011 | 184 | 0.090 |
Why?
| Neoplastic Stem Cells | 1 | 2011 | 103 | 0.090 |
Why?
| Neoplasm Recurrence, Local | 2 | 2019 | 644 | 0.090 |
Why?
| Microsatellite Instability | 1 | 2009 | 20 | 0.090 |
Why?
| Lasers, Solid-State | 1 | 2010 | 32 | 0.090 |
Why?
| Melanins | 1 | 2009 | 30 | 0.090 |
Why?
| Neoplasm Proteins | 2 | 2003 | 359 | 0.090 |
Why?
| Neoadjuvant Therapy | 1 | 2011 | 125 | 0.090 |
Why?
| Hospitals, Teaching | 1 | 2010 | 58 | 0.090 |
Why?
| Medical Records | 1 | 2010 | 92 | 0.090 |
Why?
| Mouth | 1 | 2010 | 35 | 0.090 |
Why?
| Survival Rate | 3 | 2011 | 951 | 0.090 |
Why?
| Multiple Endocrine Neoplasia Type 2a | 1 | 2009 | 6 | 0.090 |
Why?
| Vascular Surgical Procedures | 1 | 2011 | 178 | 0.090 |
Why?
| Carcinoma, Medullary | 1 | 2009 | 15 | 0.090 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2009 | 35 | 0.090 |
Why?
| Receptors, Estrogen | 1 | 2009 | 131 | 0.080 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 25 | 0.080 |
Why?
| Pilot Projects | 1 | 2011 | 808 | 0.080 |
Why?
| Port-Wine Stain | 1 | 2008 | 14 | 0.080 |
Why?
| Muscle, Smooth, Vascular | 1 | 2009 | 140 | 0.080 |
Why?
| Immunotherapy | 1 | 2011 | 263 | 0.080 |
Why?
| Early Detection of Cancer | 2 | 2022 | 162 | 0.080 |
Why?
| Blotting, Western | 3 | 2016 | 683 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1476 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2008 | 230 | 0.080 |
Why?
| Tumor Cells, Cultured | 3 | 2016 | 477 | 0.080 |
Why?
| Cytokines | 1 | 2011 | 676 | 0.080 |
Why?
| Factor VIIa | 1 | 2007 | 10 | 0.080 |
Why?
| Jaw Diseases | 1 | 2007 | 7 | 0.080 |
Why?
| Thyroid Neoplasms | 1 | 2009 | 162 | 0.070 |
Why?
| Practice Guidelines as Topic | 1 | 2010 | 492 | 0.070 |
Why?
| Practice Management, Medical | 1 | 2006 | 13 | 0.070 |
Why?
| Osteonecrosis | 1 | 2007 | 36 | 0.070 |
Why?
| Postoperative Hemorrhage | 1 | 2007 | 53 | 0.070 |
Why?
| Infant, Newborn | 2 | 2011 | 2907 | 0.070 |
Why?
| Tongue | 1 | 2007 | 41 | 0.070 |
Why?
| Bone Density Conservation Agents | 1 | 2007 | 83 | 0.070 |
Why?
| Otolaryngology | 1 | 2006 | 58 | 0.070 |
Why?
| Diphosphonates | 1 | 2007 | 96 | 0.070 |
Why?
| Cell Line, Tumor | 3 | 2015 | 1550 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2007 | 569 | 0.070 |
Why?
| Mice, Inbred NOD | 2 | 2016 | 99 | 0.070 |
Why?
| Prospective Studies | 1 | 2011 | 2604 | 0.060 |
Why?
| Mice, SCID | 2 | 2016 | 196 | 0.060 |
Why?
| Skin | 1 | 2008 | 469 | 0.060 |
Why?
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2004 | 10 | 0.060 |
Why?
| Neoplasm Metastasis | 2 | 2015 | 252 | 0.060 |
Why?
| Ataxia Telangiectasia | 1 | 2004 | 5 | 0.060 |
Why?
| DNA Repair Enzymes | 1 | 2004 | 50 | 0.060 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 232 | 0.060 |
Why?
| Cross-Sectional Studies | 2 | 2012 | 1693 | 0.060 |
Why?
| Genes, p16 | 1 | 2003 | 9 | 0.060 |
Why?
| Polymerase Chain Reaction | 4 | 2009 | 531 | 0.060 |
Why?
| Lymph Node Excision | 1 | 2004 | 140 | 0.060 |
Why?
| Proteoglycans | 1 | 2003 | 96 | 0.060 |
Why?
| Radiotherapy | 1 | 2004 | 138 | 0.060 |
Why?
| Magnetic Resonance Angiography | 2 | 2018 | 80 | 0.060 |
Why?
| Antigens, Nuclear | 2 | 2013 | 24 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2013 | 77 | 0.060 |
Why?
| Young Adult | 2 | 2012 | 4318 | 0.060 |
Why?
| Magnetic Resonance Imaging | 2 | 2007 | 1604 | 0.060 |
Why?
| Plasmodium falciparum | 1 | 2022 | 18 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 673 | 0.050 |
Why?
| Erythrocytes | 1 | 2022 | 98 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 269 | 0.050 |
Why?
| Double-Blind Method | 1 | 2002 | 742 | 0.050 |
Why?
| Survival Analysis | 3 | 2009 | 735 | 0.050 |
Why?
| Tryptases | 1 | 2018 | 4 | 0.040 |
Why?
| Estrogen Receptor beta | 1 | 2018 | 56 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2018 | 95 | 0.040 |
Why?
| Arkansas | 1 | 2004 | 2100 | 0.040 |
Why?
| Protein Transport | 1 | 2018 | 195 | 0.040 |
Why?
| Ultrasonography, Doppler | 1 | 2018 | 57 | 0.040 |
Why?
| Biopsy, Fine-Needle | 2 | 2009 | 116 | 0.040 |
Why?
| Pressure | 1 | 2017 | 120 | 0.040 |
Why?
| Cadaver | 1 | 2017 | 113 | 0.040 |
Why?
| Serum | 1 | 2016 | 39 | 0.030 |
Why?
| Molecular Imaging | 1 | 2016 | 60 | 0.030 |
Why?
| Risk Factors | 3 | 2015 | 3935 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 171 | 0.030 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 18 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 206 | 0.030 |
Why?
| Mammography | 1 | 2015 | 95 | 0.030 |
Why?
| Acetylation | 1 | 2015 | 99 | 0.030 |
Why?
| Keratin-20 | 1 | 2014 | 7 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 2015 | 64 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2014 | 21 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 426 | 0.030 |
Why?
| Chromatin | 1 | 2015 | 156 | 0.030 |
Why?
| Prognosis | 3 | 2004 | 2118 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 37 | 0.030 |
Why?
| HEK293 Cells | 1 | 2014 | 245 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2015 | 199 | 0.030 |
Why?
| Gene Expression Regulation | 1 | 2018 | 1062 | 0.030 |
Why?
| Comorbidity | 1 | 2015 | 663 | 0.030 |
Why?
| Down-Regulation | 1 | 2014 | 388 | 0.030 |
Why?
| Protein Binding | 1 | 2015 | 736 | 0.030 |
Why?
| Actins | 1 | 2013 | 132 | 0.030 |
Why?
| RNA, Messenger | 1 | 2016 | 1202 | 0.030 |
Why?
| Lymphocele | 1 | 2011 | 7 | 0.030 |
Why?
| Base Sequence | 2 | 2004 | 719 | 0.030 |
Why?
| Tissue Survival | 1 | 2011 | 12 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 55 | 0.030 |
Why?
| Tissue Culture Techniques | 1 | 2011 | 46 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1048 | 0.030 |
Why?
| Gluconates | 1 | 2011 | 1 | 0.020 |
Why?
| Neoplasms, Squamous Cell | 1 | 2011 | 9 | 0.020 |
Why?
| Cell Line | 1 | 2014 | 1153 | 0.020 |
Why?
| Indomethacin | 1 | 2011 | 40 | 0.020 |
Why?
| Graft Survival | 1 | 2011 | 165 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2011 | 58 | 0.020 |
Why?
| Interleukin-2 | 1 | 2011 | 75 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1138 | 0.020 |
Why?
| Carrier Proteins | 2 | 2003 | 359 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2011 | 92 | 0.020 |
Why?
| Cyclophosphamide | 1 | 2011 | 172 | 0.020 |
Why?
| Interferon-gamma | 1 | 2011 | 195 | 0.020 |
Why?
| Glottis | 1 | 2010 | 32 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2011 | 401 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2011 | 485 | 0.020 |
Why?
| Time Factors | 2 | 2007 | 3213 | 0.020 |
Why?
| Sclerotherapy | 1 | 2010 | 47 | 0.020 |
Why?
| Calcitonin | 1 | 2009 | 38 | 0.020 |
Why?
| Endothelial Cells | 1 | 2011 | 294 | 0.020 |
Why?
| Paraffin Embedding | 1 | 2008 | 56 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2011 | 434 | 0.020 |
Why?
| Thyroidectomy | 1 | 2009 | 103 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2009 | 656 | 0.020 |
Why?
| Dental Care | 1 | 2007 | 11 | 0.020 |
Why?
| Mouth Floor | 1 | 2007 | 5 | 0.020 |
Why?
| Polyvinyl Alcohol | 1 | 2007 | 7 | 0.020 |
Why?
| Curettage | 1 | 2007 | 15 | 0.020 |
Why?
| Signal Transduction | 1 | 2014 | 1753 | 0.020 |
Why?
| Hyperbaric Oxygenation | 1 | 2007 | 17 | 0.020 |
Why?
| Current Procedural Terminology | 1 | 2006 | 9 | 0.020 |
Why?
| Pharyngeal Diseases | 1 | 2007 | 12 | 0.020 |
Why?
| Collateral Circulation | 1 | 2007 | 41 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2006 | 24 | 0.020 |
Why?
| Cutaneous Fistula | 1 | 2007 | 16 | 0.020 |
Why?
| Neck Dissection | 1 | 2007 | 43 | 0.020 |
Why?
| Office Visits | 1 | 2006 | 49 | 0.020 |
Why?
| Fistula | 1 | 2007 | 28 | 0.020 |
Why?
| Angiography | 1 | 2007 | 147 | 0.020 |
Why?
| Salvage Therapy | 1 | 2007 | 145 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2007 | 95 | 0.020 |
Why?
| Imidazoles | 1 | 2007 | 142 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2009 | 570 | 0.020 |
Why?
| Preoperative Care | 1 | 2007 | 184 | 0.020 |
Why?
| Ultrasonography | 1 | 2006 | 480 | 0.020 |
Why?
| Guanine | 1 | 2004 | 42 | 0.020 |
Why?
| United States | 1 | 2015 | 5217 | 0.020 |
Why?
| Syndecans | 1 | 2003 | 43 | 0.010 |
Why?
| Methylation | 1 | 2004 | 130 | 0.010 |
Why?
| Syndecan-1 | 1 | 2003 | 82 | 0.010 |
Why?
| Base Pair Mismatch | 1 | 2003 | 24 | 0.010 |
Why?
| DNA Adducts | 1 | 2004 | 162 | 0.010 |
Why?
| Cell Count | 1 | 2003 | 181 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2011 | 1300 | 0.010 |
Why?
| DNA Repair | 1 | 2003 | 202 | 0.010 |
Why?
| Alcohol Drinking | 1 | 2003 | 259 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2003 | 980 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2007 | 820 | 0.010 |
Why?
| Smoking | 1 | 2003 | 556 | 0.010 |
Why?
| Multiple Myeloma | 1 | 2007 | 3035 | 0.010 |
Why?
|
|
Suen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|